Increasing inflammatory biomarkers are associated with mortality in critically ill COVID-19 patients despite anti-inflammatory treatment.

ABSTRACT: Predicting mortality in COVID-19 ARDS may support ICU clinical decision-making. Biomarkers of innate immunity, coagulation, endothelial injury, and fibroproliferation have been studied as predictors. We aimed to examine whether trends in plasma biomarkers predict ICU mortality and to explore underlying biological processes through pathway analysis. Additionally, we explored whether HDS changes biomarker trajectories in COVID-19 ARDS. In this observational study, we included patients with COVID-19 ARDS admitted to the ICU of an academic hospital in Rotterdam between February 2020 and February 2022. In repeated plasma samples, 64 biomarkers were measured. Joint modeling assessed the association between biomarker changes and ICU mortality, adjusting for age, sex, BMI, and HDS. Protein-protein

SUBMITTER: Daenen K 

PROVIDER: S-EPMC12605395 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature